Nura Bio, a clinical-stage biopharmaceutical company developing neuroprotective therapies for neurological diseases, has closed its Series A financing with an additional $68 million, raising the total to over $140 million. The round was led by The Column Group, with continued support from Samsara Bio Capital, Euclidean Capital, and new investor Sanofi Ventures.

The company also announced the appointment of Shilpa Sambashivan, Ph.D., as CEO. Dr. Sambashivan has played a key role in advancing Nura Bio’s research pipeline, including the development of its lead candidate, NB-4746, which recently completed Phase 1 studies.

Nura Bio’s NB-4746, a SARM1 inhibitor aimed at preventing axon degeneration, has shown promise in preclinical models. The company plans to initiate a Phase 1b/2 trial in patients in 2025.

Dr. Sambashivan highlighted the company’s mission to deliver novel neuroprotective therapies, emphasizing the strong support from investors as Nura Bio moves forward with clinical development.